OA12246A - Method for synthesis of N-Ä(S)-1-carboxybutylÜ-(S)-alanine esters and use in synthesis of perindopril. - Google Patents

Method for synthesis of N-Ä(S)-1-carboxybutylÜ-(S)-alanine esters and use in synthesis of perindopril. Download PDF

Info

Publication number: OA12246A
Authority: OA; OAPI
Prior art keywords: formula; compound; synthesis; process according; perindopril
Prior art date: 2000-04-11

Application number

OA1200200313A

Other languages

English (en)

Inventor

Alain Renaud

Jean-Claude Souvie

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-11

Filing date

2001-04-10

Publication date

2003-12-08

2001-04-10 Application filed by Servier Lab filed Critical Servier Lab

2003-12-08 Publication of OA12246A publication Critical patent/OA12246A/en

Links

238000000034 method Methods 0.000 title claims abstract description 17
230000015572 biosynthetic process Effects 0.000 title claims abstract description 13
238000003786 synthesis reaction Methods 0.000 title claims abstract description 12
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims abstract description 7
229960002582 perindopril Drugs 0.000 title claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 6
125000000217 alkyl group Chemical group 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
239000011541 reaction mixture Substances 0.000 claims description 6
238000001914 filtration Methods 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
235000004279 alanine Nutrition 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
230000020477 pH reduction Effects 0.000 claims description 3
238000001953 recrystallisation Methods 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
239000002244 precipitate Substances 0.000 claims description 2
230000000707 stereoselective effect Effects 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
229960003767 alanine Drugs 0.000 description 5
238000002955 isolation Methods 0.000 description 4
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
DPBOUPADTRCCIH-UHFFFAOYSA-N ethyl 2-aminopentanoate Chemical compound CCCC(N)C(=O)OCC DPBOUPADTRCCIH-UHFFFAOYSA-N 0.000 description 2
YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
239000000203 mixture Substances 0.000 description 2
AMDDRMIFTJHJGD-WDSKDSINSA-N (2s)-2-[[(1s)-1-carboxyethyl]amino]pentanoic acid Chemical class CCC[C@@H](C(O)=O)N[C@@H](C)C(O)=O AMDDRMIFTJHJGD-WDSKDSINSA-N 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
ORSIRXYHFPHWTN-UHFFFAOYSA-N ethyl 2-bromopentanoate Chemical compound CCCC(Br)C(=O)OCC ORSIRXYHFPHWTN-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/32—Preparation of optical isomers by stereospecific synthesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Indole Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200200313A 2000-04-11 2001-04-10 Method for synthesis of N-Ä(S)-1-carboxybutylÜ-(S)-alanine esters and use in synthesis of perindopril. OA12246A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0004610A FR2807430B1 (fr)	2000-04-11	2000-04-11	Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril

Publications (1)

Publication Number	Publication Date
OA12246A true OA12246A (en)	2003-12-08

Family

ID=8849107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200313A OA12246A (en)	2000-04-11	2001-04-10	Method for synthesis of N-Ä(S)-1-carboxybutylÜ-(S)-alanine esters and use in synthesis of perindopril.

Country Status (35)

Country	Link
US (1)	US6774259B2 (de)
EP (1)	EP1272454B1 (de)
JP (1)	JP3872344B2 (de)
KR (1)	KR100520700B1 (de)
CN (1)	CN1176903C (de)
AP (1)	AP1417A (de)
AR (1)	AR027782A1 (de)
AT (1)	ATE362913T1 (de)
AU (2)	AU2001250467B2 (de)
BG (1)	BG65833B1 (de)
BR (1)	BR0109963A (de)
CA (1)	CA2405466C (de)
CY (1)	CY1106720T1 (de)
CZ (1)	CZ302603B6 (de)
DE (1)	DE60128554T2 (de)
DK (1)	DK1272454T3 (de)
EA (1)	EA004265B1 (de)
EE (1)	EE05030B1 (de)
ES (1)	ES2287114T3 (de)
FR (1)	FR2807430B1 (de)
GE (1)	GEP20063798B (de)
HR (1)	HRP20020887B1 (de)
HU (1)	HU229189B1 (de)
ME (1)	ME00442B (de)
MX (1)	MXPA02009888A (de)
NO (1)	NO327970B1 (de)
NZ (1)	NZ521846A (de)
OA (1)	OA12246A (de)
PL (1)	PL346553A1 (de)
PT (1)	PT1272454E (de)
RS (1)	RS50240B (de)
SK (1)	SK287067B6 (de)
UA (1)	UA72040C2 (de)
WO (1)	WO2001056972A1 (de)
ZA (1)	ZA200207689B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2807037B1 (fr) *	2000-03-31	2002-05-10	Adir	NOUVEAU PROCEDE DE SYNTHESE DES ESTERS DE LA N-[(s)-1- CARBOXYBUTYL]-(S)-ALANINE ET APPLICATION A LA SYNTHESE DU PERINDOPRIL
FR2827860B1 (fr) *	2001-07-24	2004-12-10	Servier Lab	Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
PT1603558E (pt)	2003-02-28	2008-08-19	Servier S A Lab	Processo para a preparação de perindopril e dos seus sais
DE60329648D1 (de) *	2003-09-01	2009-11-26	Servier Lab	Neues Verfahren zur Herstellung von Estern des N-((S)-1-Carboxybutyl)-(S)-alanins und seine Verwendung in der Synthese von Perindopril
ATE315046T1 (de) *	2003-09-30	2006-02-15	Servier Lab	Verfahren zur herstellung von n-((s)-1- (etoxycarbonyl)butyl)-(s)-alanin und verwendung in der synthese von perindopril
SI1403278T1 (en) *	2003-09-30	2005-10-31	Les Laboratoires Servier	Process for the synthesis of N-((S)-1-(ethoxycarbonyl)butyl)-(S)-alanine and use in the synthese of perindopril
JP4948392B2 (ja) *	2004-03-29	2012-06-06	レラボラトアセルビエ	固形薬学的組成物を調製するためのプロセス
SI21800A (sl)	2004-05-14	2005-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nov postopek sinteze perindoprila
EP1792896A1 (de)	2005-12-01	2007-06-06	KRKA, tovarna zdravil, d.d., Novo mesto	Verfahren zur Herstellung von Perindopril und deren Salze
FI126564B (fi)	2011-02-28	2017-02-15	Andritz Oy	Menetelmä ja laitteisto meesan polttamiseksi
CN107098949B (zh) *	2017-04-20	2021-03-16	上药东英（江苏）药业有限公司	一种制备培哚普利叔丁胺盐的绿色合成新工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2503155A2 (fr) *	1980-10-02	1982-10-08	Science Union & Cie	Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4344949A (en) *	1980-10-03	1982-08-17	Warner-Lambert Company	Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4296110A (en) *	1980-10-28	1981-10-20	E. I. Du Pont De Nemours And Company	Antihypertensive I-substituted cyclic lactam-2-carboxylic acids
US4503043A (en) *	1981-12-07	1985-03-05	Warner-Lambert Company	Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids
FR2620700B1 (fr) *	1987-09-17	1990-06-01	Adir	Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2620699B1 (fr) *	1987-09-17	1990-06-01	Adir	Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2620709B1 (fr) *	1987-09-17	1990-09-07	Adir	Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese

2000
- 2000-04-11 FR FR0004610A patent/FR2807430B1/fr not_active Expired - Fee Related
2001
- 2001-03-20 PL PL01346553A patent/PL346553A1/xx not_active Application Discontinuation
- 2001-03-30 HU HU0101337A patent/HU229189B1/hu not_active IP Right Cessation
- 2001-04-09 AR ARP010101670A patent/AR027782A1/es not_active Application Discontinuation
- 2001-04-10 AP APAP/P/2002/002639A patent/AP1417A/en active
- 2001-04-10 WO PCT/FR2001/001088 patent/WO2001056972A1/fr not_active Ceased
- 2001-04-10 EE EEP200200586A patent/EE05030B1/xx not_active IP Right Cessation
- 2001-04-10 DE DE60128554T patent/DE60128554T2/de not_active Expired - Lifetime
- 2001-04-10 KR KR10-2002-7013604A patent/KR100520700B1/ko not_active Expired - Fee Related
- 2001-04-10 CZ CZ20023323A patent/CZ302603B6/cs not_active IP Right Cessation
- 2001-04-10 AU AU2001250467A patent/AU2001250467B2/en not_active Ceased
- 2001-04-10 DK DK01923776T patent/DK1272454T3/da active
- 2001-04-10 AT AT01923776T patent/ATE362913T1/de active
- 2001-04-10 CN CNB018079210A patent/CN1176903C/zh not_active Expired - Fee Related
- 2001-04-10 JP JP2001556822A patent/JP3872344B2/ja not_active Expired - Fee Related
- 2001-04-10 EP EP01923776A patent/EP1272454B1/de not_active Expired - Lifetime
- 2001-04-10 ME MEP-2008-671A patent/ME00442B/me unknown
- 2001-04-10 RS YU76702A patent/RS50240B/sr unknown
- 2001-04-10 HR HR20020887A patent/HRP20020887B1/xx not_active IP Right Cessation
- 2001-04-10 SK SK1457-2002A patent/SK287067B6/sk not_active IP Right Cessation
- 2001-04-10 NZ NZ521846A patent/NZ521846A/en not_active IP Right Cessation
- 2001-04-10 PT PT01923776T patent/PT1272454E/pt unknown
- 2001-04-10 OA OA1200200313A patent/OA12246A/en unknown
- 2001-04-10 EA EA200201049A patent/EA004265B1/ru not_active IP Right Cessation
- 2001-04-10 GE GEAP20016688A patent/GEP20063798B/en unknown
- 2001-04-10 MX MXPA02009888A patent/MXPA02009888A/es active IP Right Grant
- 2001-04-10 CA CA002405466A patent/CA2405466C/fr not_active Expired - Fee Related
- 2001-04-10 BR BR0109963-9A patent/BR0109963A/pt not_active Application Discontinuation
- 2001-04-10 US US10/257,239 patent/US6774259B2/en not_active Expired - Lifetime
- 2001-04-10 ES ES01923776T patent/ES2287114T3/es not_active Expired - Lifetime
- 2001-04-10 AU AU5046701A patent/AU5046701A/xx active Pending
- 2001-10-04 UA UA2002118916A patent/UA72040C2/uk unknown
2002
- 2002-09-25 ZA ZA200207689A patent/ZA200207689B/xx unknown
- 2002-10-04 NO NO20024811A patent/NO327970B1/no not_active IP Right Cessation
- 2002-11-04 BG BG107250A patent/BG65833B1/bg unknown
2007
- 2007-07-12 CY CY20071100924T patent/CY1106720T1/el unknown

Also Published As

Publication number	Publication date
RS50240B (sr)	2009-07-15
AU2001250467B2 (en)	2005-02-17
CZ20023323A3 (cs)	2003-01-15
CY1106720T1 (el)	2012-05-23
WO2001056972A1 (fr)	2001-08-09
HU229189B1 (hu)	2013-09-30
NO20024811L (no)	2002-10-04
NO327970B1 (no)	2009-11-02
DK1272454T3 (da)	2007-09-17
SK287067B6 (sk)	2009-11-05
US6774259B2 (en)	2004-08-10
EA004265B1 (ru)	2004-02-26
DE60128554D1 (de)	2007-07-05
GEP20063798B (en)	2006-04-25
FR2807430A1 (fr)	2001-10-12
FR2807430B1 (fr)	2002-05-17
ME00442B (me)	2011-10-10
ATE362913T1 (de)	2007-06-15
EE200200586A (et)	2004-04-15
AR027782A1 (es)	2003-04-09
EP1272454A1 (de)	2003-01-08
ZA200207689B (en)	2003-09-25
YU76702A (sh)	2006-05-25
BR0109963A (pt)	2003-08-05
HK1053300A1 (en)	2003-10-17
CN1176903C (zh)	2004-11-24
EA200201049A1 (ru)	2003-02-27
HRP20020887B1 (en)	2011-03-31
BG107250A (bg)	2003-06-30
KR20020093902A (ko)	2002-12-16
BG65833B1 (bg)	2010-02-26
AP1417A (en)	2005-05-24
US20030109743A1 (en)	2003-06-12
AU5046701A (en)	2001-08-14
HUP0101337A2 (hu)	2001-11-28
DE60128554T2 (de)	2008-02-21
KR100520700B1 (ko)	2005-10-17
CN1422245A (zh)	2003-06-04
PT1272454E (pt)	2007-08-01
CA2405466C (fr)	2005-02-15
ES2287114T3 (es)	2007-12-16
PL346553A1 (en)	2001-09-10
AP2002002639A0 (en)	2002-09-30
SK14572002A3 (sk)	2003-02-04
EP1272454B1 (de)	2007-05-23
CZ302603B6 (cs)	2011-08-03
JP3872344B2 (ja)	2007-01-24
HU0101337D0 (en)	2001-06-28
JP2003521530A (ja)	2003-07-15
MXPA02009888A (es)	2004-09-06
UA72040C2 (en)	2005-01-17
HUP0101337A3 (en)	2002-11-28
CA2405466A1 (fr)	2001-08-09
HRP20020887A2 (en)	2004-02-29
EE05030B1 (et)	2008-06-16
NZ521846A (en)	2004-07-30
NO20024811D0 (no)	2002-10-04

Publication	Publication Date	Title
CZ20023291A3 (cs)	2003-02-12	Způsob syntézy perindoprilu a jeho farmaceuticky přijatelných solí
AU2001250467B2 (en)	2005-02-17	Method for synthesis of N-[(S)-1-carboxybutyl]-(S)-alanine esters and use in synthesis of perindopril
US6818788B2 (en)	2004-11-16	Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril
JP4279871B2 (ja)	2009-06-17	（２ｓ，３ａｓ，７ａｓ）−１−［（ｓ）−アラニル］−オクタヒドロ−１ｈ−インドール−２−カルボン酸誘導体類を合成する新規な方法およびペリンドプリル合成におけるその使用
US20060252958A1 (en)	2006-11-09	Novel method for synthesizing esters of n-[(s)-1-carboxybutyl]-(s)-alanine and use thereof for synthesizing perindopril
HK1053300B (en)	2005-04-01	Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril
WO2006006183A2 (en)	2006-01-19	An improved process for the preparation of n-[(s)-ethoxycarbonyl-l-butyl]-(s)-alanine